Generic Effexor Xr ( Venlafaxine )

Buy Generic Effexor Xr (Venlafaxine) without prescription in Canada

In our Canadian pharmacy, you can buy Effexor XR (Venlafaxine) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Effexor XR (venlafaxine hydrochloride extended‑release) is a serotonin‑norepinephrine reuptake inhibitor (SNRI) antidepressant used to treat major depressive disorder, generalised anxiety disorder, social anxiety disorder, and panic disorder in adults. It works by increasing the levels of serotonin and norepinephrine, two neurotransmitters in the brain that help regulate mood, anxiety, and the stress response. This dual action makes it particularly effective for patients whose depression is accompanied by significant anxiety, as well as for those with anxiety disorders alone.

Usual adult dose: The usual starting dose is 75 mg taken once daily with food. For most patients, the recommended target dose is 150 mg once daily, which may be reached after 1 to 2 weeks at 75 mg daily, provided the medication is well tolerated. The maximum dose is 225 mg per day for depression and most anxiety disorders; doses above 150 mg should be given in divided doses if the total exceeds 225 mg daily. For panic disorder, an initial dose of 37.5 mg once daily for the first 4 to 7 days is recommended before increasing to 75 mg daily, to improve tolerability.

Dosage form: Extended‑release (XR) capsules available in 37.5 mg, 75 mg, and 150 mg strengths. The 75 mg and 150 mg capsules are the most commonly prescribed strengths for once‑daily maintenance therapy.

Onset of action: Some improvement in sleep, energy, or anxiety may be noticed within the first 1 to 2 weeks of treatment. The full antidepressant and anxiolytic effect typically develops over 4 to 6 weeks of continuous therapy.

Duration of action: The extended‑release formulation is designed to release venlafaxine slowly over 24 hours, providing steady blood levels with once‑daily dosing. The elimination half‑life of venlafaxine is approximately 5 hours, and its active metabolite O‑desmethylvenlafaxine has a half‑life of approximately 11 hours.

Alcohol recommendation: Alcohol consumption should be avoided during treatment with Effexor XR. Alcohol can worsen depression and anxiety, increase the risk of sedation and dizziness, and may interfere with the effectiveness of the medication. Concurrent alcohol use may also increase the risk of liver injury.

Most common side effects: Nausea, drowsiness, dry mouth, dizziness, insomnia, constipation, increased sweating, decreased appetite, and sexual dysfunction (delayed ejaculation, anorgasmia, decreased libido). Nausea is most common during the first week of therapy and usually diminishes with continued treatment. Effexor XR may cause a dose‑related increase in blood pressure, particularly at doses above 150 mg per day.

Would you like to try Effexor XR (Venlafaxine) without a prescription?

General Information about Effexor XR (Venlafaxine)

• INN (International Nonproprietary Name): Venlafaxine (as venlafaxine hydrochloride).
• Brand names available in Canada: Effexor XR® (BGP Pharma ULC, a division of Pfizer Canada Inc.). Generic versions include APO‑Venlafaxine XR (Apotex Inc.), TEVA‑Venlafaxine XR (Teva Canada Limited), Sandoz Venlafaxine XR (Sandoz Canada Inc.), PMS‑Venlafaxine XR (Pharmascience Inc.), JAMP‑Venlafaxine XR (JAMP Pharma Corporation), M‑Venlafaxine XR (Mantra Pharma Inc.), and many others.
• ATC code: N06AX16.
• Dosage forms and strengths: Extended‑release (XR) capsules: 37.5 mg, 75 mg, and 150 mg (as venlafaxine hydrochloride). The 75 mg and 150 mg capsules are the core strengths for maintenance dosing.
• Manufacturers in Canada: BGP Pharma ULC (Pfizer), Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., JAMP Pharma Corporation, Mantra Pharma Inc., and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Marketed (DINs: Effexor XR 37.5 mg – 02237270, 75 mg – 02237271, 150 mg – 02237272). Generic formulations are widely available.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act.

Mechanism of Action and Pharmacology

Venlafaxine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). Its primary mechanism of action is the potent inhibition of the presynaptic reuptake of serotonin (5‑hydroxytryptamine, 5‑HT) and norepinephrine (NE) by blocking the serotonin transporter (SERT) and the norepinephrine transporter (NET), respectively. At lower doses (75 mg/day), venlafaxine acts primarily as a serotonin reuptake inhibitor; at higher doses (150 mg/day and above), the noradrenergic effect becomes more pronounced. This dose‑dependent dual reuptake inhibition is thought to contribute to its broad efficacy across depressive and anxiety disorders.

Venlafaxine has no significant affinity for muscarinic cholinergic, histaminergic, or alpha‑1 adrenergic receptors, which accounts for a relatively favourable side‑effect profile compared with older tricyclic antidepressants. However, its noradrenergic effects can lead to dose‑related increases in blood pressure. Venlafaxine is extensively metabolised in the liver, primarily by cytochrome P450 2D6, to its major active metabolite, O‑desmethylvenlafaxine (desvenlafaxine), which is pharmacologically equipotent to the parent compound. The extended‑release formulation (Effexor XR) provides a slower rate of absorption, resulting in a flatter plasma concentration‑time profile and allowing once‑daily dosing. The elimination half‑life of venlafaxine is approximately 5 hours (± 2 hours), and that of O‑desmethylvenlafaxine is 11 hours (± 2 hours). Steady‑state concentrations are achieved within 3 days of regular administration. Venlafaxine and its metabolites are excreted primarily via the kidneys.

Indications

• Major Depressive Disorder (MDD): For the treatment of major depressive disorder in adults. Efficacy has been demonstrated in short‑term trials and in maintenance studies for up to 12 months.
• Generalised Anxiety Disorder (GAD): For the treatment of generalised anxiety disorder in adults. Efficacy has been demonstrated in short‑term trials of up to 6 months.
• Social Anxiety Disorder (Social Phobia): For the treatment of social anxiety disorder in adults. Efficacy has been demonstrated in short‑term trials of up to 12 weeks.
• Panic Disorder: For the treatment of panic disorder, with or without agoraphobia, in adults. Efficacy has been demonstrated in short‑term trials of up to 12 weeks.
• Effexor XR is not approved for use in children and adolescents under 18 years of age. Safety and efficacy in paediatric populations have not been established.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Venlafaxine should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the foetus. Infants exposed to SNRIs late in the third trimester may develop complications requiring prolonged hospitalisation, respiratory support, and tube feeding. There is a potential for increased risk of postpartum hemorrhage with drugs that affect serotonin reuptake.
• Breastfeeding: Venlafaxine and its active metabolite are excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.
• Paediatrics (< 18 years): Safety and efficacy have not been established in children and adolescents. Antidepressants increase the risk of suicidal thinking and behaviour in children, adolescents, and young adults.
• Elderly: No specific dose adjustment is required based on age alone. However, elderly patients may be more sensitive to the adverse effects of venlafaxine, including hyponatraemia, orthostatic hypotension, and an increased risk of falls. Caution is advised.
• Hepatic impairment: The dose of venlafaxine should be reduced by 50% in patients with moderate to severe hepatic impairment. In patients with mild hepatic impairment, consider a dose reduction of 50%.
• Renal impairment: The dose of venlafaxine should be reduced by 25% in patients with moderate renal impairment (GFR 30–60 mL/min) and by 50% in patients on haemodialysis. The total daily dose should be reduced by 50% in patients with severe renal impairment (GFR < 30 mL/min).
• Cardiovascular disease: Venlafaxine may cause sustained increases in blood pressure, particularly at doses above 150 mg/day. Blood pressure should be assessed before initiating therapy and monitored periodically. Use with caution in patients with pre‑existing hypertension, recent myocardial infarction, unstable cardiac disease, or congestive heart failure.
• Bipolar disorder: Screen for bipolar disorder before initiating treatment. Venlafaxine may precipitate a manic or hypomanic episode in patients with undiagnosed bipolar disorder.
• Seizure disorders: Venlafaxine may lower the seizure threshold. Use with caution in patients with epilepsy or a history of seizures.
• Angle‑closure glaucoma: Venlafaxine can cause pupillary dilation, which may trigger an acute attack of angle‑closure glaucoma in susceptible individuals.
• Hyponatraemia: Cases of hyponatraemia have been reported with serotonergic antidepressants, including venlafaxine. Caution is advised in elderly patients, those taking diuretics, and those who are volume‑depleted.
• Abnormal bleeding: Venlafaxine, like other serotonergic antidepressants, may increase the risk of bleeding events, including gastrointestinal and cutaneous bleeding. Caution is advised in patients taking anticoagulants or antiplatelet agents.
• Serotonin syndrome: A potentially life‑threatening serotonin syndrome may occur with venlafaxine, particularly when combined with other serotonergic drugs. Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms. Immediate medical attention is required.
• Discontinuation syndrome: Abrupt discontinuation of venlafaxine may cause withdrawal symptoms including dizziness, nausea, headache, paraesthesia, irritability, nightmares, insomnia, and anxiety. A gradual dose reduction over at least 1 to 2 weeks is recommended.
• Allergy: Do not take Effexor XR if you have a known hypersensitivity to venlafaxine hydrochloride or any excipient in the formulation.

Driving and alcohol

Effexor XR may cause dizziness, drowsiness, and impaired cognitive and motor skills. Patients should be cautioned about driving or operating hazardous machinery until they are reasonably certain that venlafaxine does not adversely affect their mental alertness and motor coordination. Alcohol consumption should be avoided during treatment with Effexor XR. Alcohol can worsen depression and anxiety, increase the risk of sedation and dizziness, and may interfere with the effectiveness of the medication. Concurrent alcohol use may also increase the risk of liver injury.

Dosage Instructions

• Major Depressive Disorder: The recommended starting dose is 75 mg once daily with food. After 1 to 2 weeks, the dose may be increased to 150 mg once daily if needed. Doses above 150 mg per day up to a maximum of 225 mg per day may be considered in patients with more severe depression or who have not responded to lower doses.
• Generalised Anxiety Disorder: The recommended starting dose is 75 mg once daily with food. The dose may be increased by 75 mg/day at intervals of at least 4 days, up to a maximum of 225 mg/day.
• Social Anxiety Disorder: The recommended dose is 75 mg once daily with food. There is no evidence that higher doses confer additional benefit.
• Panic Disorder: The recommended starting dose is 37.5 mg once daily for the first 4 to 7 days, followed by an increase to 75 mg once daily. If no response is seen after several weeks, the dose may be increased to 150 mg/day or a maximum of 225 mg/day. A dose increase beyond 75 mg/day should be made in increments of 37.5 mg/day or 75 mg/day at intervals of at least 4 days.
• Elderly: No routine dose adjustment based on age alone. However, use the lowest effective dose and monitor closely.
• Hepatic impairment: Reduce the dose by 50% in patients with moderate to severe hepatic impairment. Consider a dose reduction of 50% in mild hepatic impairment.
• Renal impairment: Reduce the dose by 25% in moderate renal impairment; reduce by 50% in severe renal impairment and in patients on haemodialysis.
• Administration: Effexor XR capsules should be swallowed whole with fluid at approximately the same time each day, preferably with food. Do not crush, chew, or dissolve the capsules. The capsules may be opened and the contents sprinkled onto a spoonful of applesauce, which should be swallowed immediately without chewing; this is followed by a glass of water.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose.
• Discontinuation: Gradual dose reduction over at least 1 to 2 weeks is recommended. For patients on Effexor XR 150 mg or more, reducing by 75 mg per day each week may be appropriate. Patients should be monitored for withdrawal symptoms during the taper period.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Nausea (30‑37%), headache (25‑34%), dizziness (19‑24%), insomnia (18‑24%), somnolence (17‑23%), dry mouth (12‑22%), hyperhidrosis (12‑19%), and constipation (11‑15%). Nausea is most common during the first week and tends to diminish with continued treatment.
• Common side effects (1‑10%): Decreased appetite (8‑20%), nervousness (6‑13%), tremor (3‑7%), blurred vision (4‑6%), diarrhoea (6‑8%), vomiting (3‑6%), fatigue (8‑12%), abnormal ejaculation/orgasm (2‑16%), and erectile dysfunction (2‑10%).
• Blood pressure effects: Venlafaxine may cause sustained increases in blood pressure, which are dose‑dependent. Clinically significant increases in blood pressure (defined as an increase of ≥ 15 mm Hg in supine diastolic blood pressure to ≥ 105 mm Hg) occur in approximately 3‑7% of patients at doses of 75‑150 mg/day, and in up to 13% at doses above 300 mg/day. Regular blood pressure monitoring is recommended.
• Serious adverse reactions: Serotonin syndrome, neuroleptic malignant syndrome‑like reactions, severe cutaneous adverse reactions (including Stevens‑Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme), hyponatraemia (more common in the elderly and volume‑depleted), interstitial lung disease, eosinophilic pneumonia, pancreatitis, hepatitis, and seizures. Activation of mania or hypomania may occur in patients with bipolar disorder.
• Discontinuation symptoms: Abrupt discontinuation may cause dizziness, nausea, headache, paraesthesia, vomiting, irritability, nightmares, insomnia, and anxiety. Venlafaxine is associated with a higher incidence of discontinuation symptoms than many other antidepressants due to its relatively short half‑life. A gradual dose taper is essential.
• Contraindications: Hypersensitivity to venlafaxine hydrochloride or any excipient in the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs), including linezolid and intravenous methylene blue. Starting venlafaxine in a patient who is being treated with an MAOI, or within 14 days of discontinuing an MAOI. Starting an MAOI in a patient who is being treated with venlafaxine, or within 7 days of discontinuing venlafaxine.

Drug Interactions

• Monoamine oxidase inhibitors (MAOIs) — contraindicated: Concomitant use of venlafaxine with MAOIs, including linezolid and intravenous methylene blue, increases the risk of serotonin syndrome and is contraindicated. A 14‑day washout is required before starting venlafaxine after stopping an MAOI, and a 7‑day washout before starting an MAOI after stopping venlafaxine.
• Other serotonergic drugs: Concomitant use with SSRIs, other SNRIs, tricyclic antidepressants, triptans, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St. John's wort increases the risk of serotonin syndrome. Monitor closely if co‑administration is necessary.
• CNS depressants: Alcohol, benzodiazepines, opioids, and other CNS depressants may increase the sedative and psychomotor‑impairing effects of venlafaxine.
• CYP2D6 inhibitors: Paroxetine, fluoxetine, bupropion, and quinidine may increase venlafaxine plasma concentrations, particularly in CYP2D6 poor metabolisers. No specific dose adjustment is recommended, but caution is advised.
• CYP3A4 inhibitors and inducers: Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) may increase venlafaxine plasma levels. Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease venlafaxine plasma levels, potentially reducing efficacy.
• Anticoagulants and antiplatelet agents: Venlafaxine may increase the risk of bleeding when co‑administered with warfarin, aspirin, clopidogrel, and NSAIDs. Monitor INR in patients taking warfarin.
• Antihypertensives: Venlafaxine may increase blood pressure and could theoretically antagonise the effects of antihypertensive medications. Blood pressure should be monitored.
• Weight‑loss agents: Venlafaxine combined with phentermine, fenfluramine, or dexfenfluramine has been associated with reports of serotonin syndrome; such combinations are not recommended.
• Alcohol: Alcohol should be avoided, as it may worsen depression and increase sedation.

Practical Advice

• Administration: Take Effexor XR once daily with food, at approximately the same time each day. Swallow the capsule whole with fluid; do not crush, chew, or dissolve it. If you have difficulty swallowing, the capsule may be opened and the contents sprinkled onto a spoonful of applesauce; swallow immediately without chewing, then drink a glass of water. Taking the medication with food helps reduce nausea.
• Monitoring: Regular follow‑up with your doctor is essential, particularly during the first weeks of treatment and after dosage changes. Blood pressure should be measured before starting treatment and periodically during therapy. Monitor for clinical worsening, emergence of suicidal thoughts or behaviour, and unusual changes in mood or behaviour. Serum sodium should be checked in patients at risk of hyponatraemia. Liver function tests may be considered periodically.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep out of the reach and sight of children.
• Lifestyle: Effexor XR is most effective when used as part of a comprehensive treatment plan that includes psychotherapy, lifestyle changes, and social support. Maintain a balanced diet and regular sleep schedule. Avoid alcohol and recreational drugs. Do not drive or operate heavy machinery until you know how the medication affects you. Rising slowly from a sitting or lying position may help minimise dizziness.
• Missed dose: If you miss a dose, take it as soon as remembered on the same day. If it is close to the time of your next dose, skip the missed dose and resume your regular schedule. Do not double the dose.
• When to seek medical review: Contact your doctor immediately if you experience signs of serotonin syndrome (agitation, confusion, rapid heart rate, high fever, muscle rigidity, seizures), a manic episode (extreme elation, racing thoughts, risk‑taking behaviour), signs of liver injury (jaundice, dark urine, severe fatigue), abnormal bleeding, severe allergic reaction (rash, swelling of the face, tongue, or throat, difficulty breathing), or worsening depression with suicidal thoughts. If you are planning to become pregnant, are pregnant, or are breastfeeding, consult your doctor.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Selective serotonin reuptake inhibitors (SSRIs): Sertraline (Zoloft), escitalopram (Cipralex), fluoxetine (Prozac), paroxetine (Paxil), and citalopram (Celexa) are first‑line antidepressants for major depressive disorder and anxiety disorders. They act primarily on serotonin and may be better tolerated by some patients, but they may be less effective than venlafaxine for severe depression with melancholic features.
• Other SNRIs: Duloxetine (Cymbalta) and desvenlafaxine (Pristiq) are first‑line agents that target both serotonin and norepinephrine. Desvenlafaxine is the active metabolite of venlafaxine and offers a more predictable pharmacokinetic profile with fewer drug interactions. Duloxetine has additional approved indications for neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.
• Mirtazapine (Remeron): An atypical antidepressant that enhances norepinephrine and serotonin release. It provides sedation and appetite stimulation, making it useful for patients with insomnia and poor appetite, but it commonly causes weight gain.
• Bupropion (Wellbutrin): An NDRI antidepressant with a low incidence of sexual dysfunction and weight gain. It lacks the serotonin effects of venlafaxine and is not effective for anxiety disorders; it may be preferred for depression with prominent fatigue or hypersomnia.
• Tricyclic antidepressants (TCAs): Amitriptyline (Elavil) and nortriptyline (Aventyl) are older agents with established efficacy for depression and neuropathic pain. They carry a higher burden of anticholinergic side effects, sedation, and cardiotoxicity in overdose.
• Benzodiazepines: Lorazepam (Ativan), clonazepam (Rivotril), and alprazolam (Xanax) may be used short‑term for acute anxiety but are not recommended for long‑term management due to the risk of dependence. They do not treat the underlying depression.
• Non‑pharmacological approaches: Cognitive behavioural therapy (CBT), interpersonal therapy (IPT), and behavioural activation are evidence‑based psychotherapies for depression. For anxiety disorders, CBT is a first‑line treatment. Exercise, mindfulness‑based stress reduction, and good sleep hygiene are important complementary measures.

Clinical Efficacy

The efficacy of venlafaxine for the treatment of major depressive disorder and anxiety disorders has been established in numerous randomised, double‑blind, placebo‑controlled clinical trials. In major depressive disorder, venlafaxine 75–150 mg/day produced a significantly greater reduction in depression rating scale scores compared with placebo, with response rates of approximately 60‑70%. A meta‑analysis of 34 studies found that venlafaxine was statistically significantly more effective than SSRIs as a class, with a remission rate advantage of approximately 5‑7%. This finding has been replicated in several large, independent analyses, and venlafaxine is one of the few antidepressants for which a statistically significant superiority over SSRIs has been demonstrated consistently.

In generalised anxiety disorder, venlafaxine XR 75–225 mg/day produced significant improvements in the Hamilton Anxiety Rating Scale (HAM‑A) compared with placebo, with response rates of 50‑60%. In social anxiety disorder and panic disorder, venlafaxine XR was significantly superior to placebo in reducing symptom severity. In short‑term trials, venlafaxine demonstrated comparable efficacy to paroxetine and other active comparators, and was superior to placebo.

Venlafaxine is also effective for preventing relapse and recurrence in long‑term maintenance studies. Patients who responded to acute treatment and were continued on venlafaxine had a significantly lower rate of depressive relapse over 6‑12 months compared with those switched to placebo. Similar maintenance benefits have been observed for generalised anxiety disorder.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 clinical guidelines list venlafaxine as a first‑line pharmacological treatment for major depressive disorder, generalised anxiety disorder, social anxiety disorder, and panic disorder in adults. It is particularly recommended for patients with severe depression, melancholic features, or those who have not responded to an SSRI. The most important tolerability considerations with venlafaxine are treatment‑emergent nausea, dose‑dependent blood pressure elevation, and a high incidence of discontinuation symptoms if the drug is stopped abruptly. Gradual tapering is essential.

Important:

Effexor XR (venlafaxine) is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It carries a boxed warning for an increased risk of suicidal thinking and behaviour in children, adolescents, and young adults under 24 years of age. All patients, regardless of age, should be closely monitored for clinical worsening, suicidality, or unusual changes in behaviour, particularly during the first few months of treatment and after dosage changes. Venlafaxine can cause sustained increases in blood pressure, especially at doses above 150 mg/day; blood pressure must be monitored before and during treatment. Do not discontinue this medication abruptly; a gradual taper over at least 1 to 2 weeks is required to minimise the risk of withdrawal symptoms, which can be severe. A rare but potentially life‑threatening serotonin syndrome may occur, particularly when venlafaxine is combined with other serotonergic drugs. If you experience agitation, confusion, rapid heart rate, high fever, muscle rigidity, or seizures, seek emergency medical attention immediately. Venlafaxine is contraindicated with MAOIs; a 14‑day washout is required before starting venlafaxine after stopping an MAOI, and a 7‑day washout is required before starting an MAOI after stopping venlafaxine. Avoid alcohol during treatment. If you are planning to become pregnant, are pregnant, or are breastfeeding, inform your doctor. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Effexor Xr - Shipping across Canada